Letybo

Botulinum toxin type A, the active ingredient in Letybo, is a muscle relaxant presented as a sterile injectable for intramuscular use. It works by reducing excessive muscle activity in conditions such as cervical dystonia, spasticity, and chronic migraine.\n\nGNH India supplies Letybo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Letybo, a botulinum toxin type A preparation, is used in several neuromuscular disorders where excessive muscle contraction is problematic.\n\n- Cervical dystonia: reduces abnormal neck muscle contractions and associated pain.\n- Blepharospasm: relaxes overactive eyelid muscles to improve eye closure control.\n- Chronic migraine: decreases frequency of migraine attacks when injected in specific head muscles.\n- Upper‑limb spasticity: diminishes muscle tone in post‑stroke or cerebral palsy patients.\n- Primary axillary hyperhidrosis: limits sweat gland activity to reduce excessive under‑arm sweating.

Adverse reactions are generally related to the injection site and the pharmacologic action of the toxin.\n\nCommon Side Effects:\n- Injection‑site pain or tenderness.\n- Bruising or erythema at the injection site.\n- Headache or flu‑like symptoms.\n- Transient localized muscle weakness.\n- Dry mouth or mild dysphagia.\n\nSerious or Rare Side Effects:\n- Diffuse muscle weakness leading to dysphagia or respiratory compromise.\n- Botulism‑like systemic spread of toxin effect.\n- Anaphylactic or severe hypersensitivity reactions.\n- Vision changes such as blurred vision or diplopia.\n- Persistent urinary retention or constipation.

Before prescribing Letybo, clinicians should evaluate patient history and potential risk factors.\n\n- Contraindication: Known hypersensitivity to botulinum toxin or any formulation component.\n- Caution: Use in patients with neuromuscular disorders (e.g., myasthenia gravis) as they may be more susceptible to systemic effects.\n- Pregnancy: Safety not established; avoid unless benefit outweighs potential risk.\n- Breastfeeding: Limited data; consider discontinuation if possible.\n- Interaction: Avoid concurrent use with other botulinum toxin products to prevent cumulative toxicity.\n- Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Botulinum toxin type A can interact with several drug classes, altering its safety profile.\n\nMajor Interactions (Avoid):\n- Aminoglycoside antibiotics (e.g., gentamicin) that potentiate neuromuscular blockade.\n- Other botulinum toxin preparations, which increase risk of systemic spread.\n- Muscle relaxants (e.g., baclofen) that may exacerbate weakness.\n- Cholinesterase inhibitors (e.g., pyridostigmine) that could counteract toxin effect.\n\nModerate Interactions (Monitor Closely):\n- Anticholinergic agents that may influence autonomic side effects.\n- Beta‑adrenergic blockers that could affect cardiovascular response.\n- Drugs affecting protein synthesis, potentially modifying toxin metabolism.